Next Phase Newsletter

By Tinotenda Chanakira, CEO of Revnuu | Life Sciences Commercialization Strategist (Special Guest Contributor)

In the life sciences, great science isn’t enough to make it out of the lab. Across biotech, medtech, and diagnostics, many teams are advancing transformative healthcare innovations—but still struggle to secure the funding, partnerships, or clinical traction they need. The culprit is rarely bad research, data or scientific innovation. More often, it’s an unclear or underdeveloped narrative.

Too often, life sciences companies present their breakthroughs in ways that prioritize technical complexity over clarity and resonance —visually and orally. Their decks are filled with mechanism-of-action diagrams, regulatory timelines, and patent claims—but little about real-world human impact. Meanwhile, capital markets are tightening, partner deal cycles are lengthening, and competition for attention has never been fiercer. In this environment, storytelling isn’t a marketing tactic. It’s a core business competency.

The challenge is that life sciences companies must communicate across very different audiences. Technical stakeholders—Key Opinion Leaders (KOLs), regulators, clinical advisors—require precision and depth. Commercial stakeholders—investors, distributors, potential acquirers—want proof of market potential and differentiation. And at the center of it all, patients and physicians seek hope, clarity, and relevance.

When a company’s narrative fractures across these touchpoints, the result is confusion, inconsistency, and distrust. Alignment stalls. Partnerships hesitate. Capital walks. To avoid this, founders and leadership teams must develop a coherent, multi-layered story that is not only technically sound but also emotionally and strategically compelling.

Over time, I’ve found that the most successful companies tend to master four core narratives. While the terms themselves have been shaped by broader industry dialogue—especially the work of Life Science Nation—this is how I’ve seen them come to life across real-world negotiations and commercialization journeys.

1. The Founder’s Core Motivation

Investors fund conviction as much as they fund IP. A founder’s story becomes the emotional and philosophical backbone of the venture. In life sciences, this often stems from a moment of deep personal or clinical proximity to the problem—a diagnostic delay, a therapeutic failure, or the loss of someone close.

The most resonant founder narratives don’t just showcase academic credentials. They surface the “why” behind the work. One oncology startup I advised pivoted its entire strategy when the founder lost a parent to late-stage metastasis. That story reshaped how partners viewed the company—not just as a platform, but as a mission-driven force.

2. From Lab to Life-Changing Impact

In science-based ventures, it’s easy to over-index on technical novelty. But partners don’t invest in “clever.” They invest in outcomes. The core question your technology story must answer is: What becomes possible now that wasn’t before?

In life sciences, this means anchoring your innovation in patient outcomes—not just mechanisms. “Our CRISPR-edited CAR-T therapy reduces relapse rates by 47% in refractory ALL” communicates far more than “novel lipid nanoparticle delivery system.” Precision and proof points win here. In fact, 83% of business development executives cite “clear patient impact language” as the single most missing element in pitch materials (LSN Survey, 2024).

3. When Treatment Becomes Transformation
Human outcomes are more compelling than preclinical data—always. This story focuses on transformation: how lives change because of what your product enables. Whether it’s earlier diagnosis, improved quality of life, or reduced healthcare burden, this is where the emotional gravity sits.

But emotion alone isn’t enough. The most effective patient stories also tie into economic logic. For example: “Maria’s Stage I diagnosis saved $218,000 in late-stage care costs.” That intersection of human and system-level impact is what resonates with both payers and partners.

4. From Validation to Velocity
Finally, partners want to see signals of commercial discipline. This doesn’t mean focusing solely on how much funding you’ve raised. Instead, highlight validation milestones that reduce perceived risk—real-world pilots, clinical endpoints, regulatory wins.

“CE Mark secured with 94% sensitivity in a real-world cohort” tells a far more powerful story than “Closed $20M Series B.” The emphasis should always be on de-risking through traction—not just hype.

These four stories don’t live in a pitch deck—they live across your organization. They must be practiced, refined, and embedded from leadership through to field teams. When aligned, they help companies accelerate partnership timelines, deepen investor conviction, and drive internal cohesion across functions.

If you’re unsure whether your narratives are aligned, ask yourself:

• Can our team clearly articulate the founder’s “why” without defaulting to credentials?
• Do our technology explanations compel clinicians to lean in?
• Do our patient stories move decision-makers beyond the data?
• Do our commercial milestones give partners confidence in our go-to-market plan?

If the answer to any of these is “no,” then it’s time to sharpen the story. Because in this industry, the science must speak—but the story must win.

About the Author
Tinotenda Chanakira is the founder and CEO of Revnuu, a commercialization strategy firm serving deep tech and life sciences ventures globally. With over 50 clients supported across Europe, North America, and the EMEA regions, Revnuu helps founders turn scientific breakthroughs into scalable, market-ready impact. The firm operates between Barcelona and Basel, guiding companies through the real-world complexities of product, capital, and growth.

Tags: business, entrepreneurship, startups, technology, venture capital

By Greg Mannix, VP, EMEA Business Development, LSN

The first week of December marks the largest life science partnering and venture week in the UK. If you’re raising pre-seed, seed, round A or round B, or are in phase 2 or earlier development, Life Science Nation’s (LSN) RESI London, One Nucleus’ Gensis, and ELRIG/SLAS events offer far better partnering, investment, learning, and procurement opportunities compared to the health care week in late November (concurrent with the Jefferies investment banking event), for a fraction of the cost. That week tends to focus on recent IPOs and companies that are close to IPO, along with phase 3 or more advanced companies looking for partnerships. If you’re not at that stage, save your critical conference and travel budgets for an event series that’s right for you.

RESI London and Gensis are combining to offer a multi-day investment, partnering and thought leadership event for venture stage companies seeking funding and strategic alliances:

December 2nd

• Free course on fundraising, including networking, offered by LSN
• Free ELRIG / SLAS drug-discovery focused networking event
• Genesis welcome reception for Genesis and RESI registrants

December 3rd

• Genesis “Maximising Returns from Life Science Innovation” KOL & partnering event
• Genesis evening reception

December 4th

• RESI London fundraising & partnering event, featuring 200 investors & in-licensors
• RESI London evening reception

During the entire week you are also welcome to attend the Genesis Fringe events for free including networking breakfasts, lunches and other events with topics similar to Building a World Class Life Science Ecosystem, Accessing US Investors and Exits, IP Strategies in Advanced Therapy Dealmaking, Top Talent Trends for Life Sciences in 2025 and Pay Transparency, R&D to Commercialization in Rare Diseases, and more.

Join us in the rich life science ecosystem in London during the first week of December. To learn more, contact us at RESI@lifesciencenation.com

Tags: business, entrepreneurship, startups, technology, venture capital